[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-405231-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-405231-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","oral-pre-exposure-prophylaxis-prep-for-hiv-prevention-clinical-effectiveness-safety-adherence-and-risk-compensation","Oral Pre-Exposure Prophylaxis (PrEP) for HIV Prevention - Clinical Effectiveness, Safety, Adherence, and Risk Compensation","","Oral pre-exposure prophylaxis (PrEP) for HIV prevention is assessed for clinical effectiveness, safety, adherence, and risk compensation across population groups. A literature review draws on WHO and UNAIDS reports and searches major databases including Google Scholar, PubMed, Science Direct, and The Lancet. From identified records, 20 studies meet inclusion criteria for qualitative synthesis. Evidence indicates very strong support for PrEP’s safety and effectiveness in MSM and serodiscordant couples when adherence is adequate, emphasizing supportive care and frequent HIV testing to reduce resistance risk.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/oral-pre-exposure-prophylaxis-prep-for-hiv-prevention-clinical-effectiveness-safety-adherence-and-risk-compensation/405231/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/oral-pre-exposure-prophylaxis-prep-for-hiv-prevention-clinical-effectiveness-safety-adherence-and-risk-compensation/405231.png","ImageObject",300,407,{"name":42,"@type":43},"Franzy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-28",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study’s objective regarding PrEP for HIV prevention?","Question",{"text":63,"@type":64},"To examine literature on the clinical efficacy, safety, adherence/compliance, and risk compensation of oral pre-exposure prophylaxis (PrEP) across all population groups.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which databases were used for the literature review?",{"text":68,"@type":64},"The review used Google Scholar, PubMed, Science Direct, and The Lancet to identify national and international articles about PrEP for preventing HIV transmission.",{"name":70,"@type":61,"acceptedAnswer":71},"What key conclusion does the study reach about PrEP’s effectiveness and safety?",{"text":72,"@type":64},"PrEP is concluded to have very strong evidence for being safe and effective for HIV prevention in MSM and serodiscordant couples, assuming adequate compliance, with emphasis on supportive care and frequent HIV testing.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},405231,1790716976,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},2336478945519,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Oral Pre-Exposure Prophylaxis (PrEP) for HIV Prevention, Clinical Effectiveness, Safety, Adherence, and Risk Compensation in all Populations  \nIbrahim Tomi1*, Eamon O'Murchu2, Liam Marshall3, Conor Teljeur4, Patricia Harrington5, Catherine Hayes6, Patrick Moran7, Mairin Ryan8  \n1 Department of Public Health, Master of Public Health, Institut Ilmu Kesehatan STRADA Indonesia  \n2 Department of Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin, Ireland  \n3,6Department of Centre for Health Policy and Management, Trinity College Dublin, Ireland  \n4,7Department of TCD Institute of Population Health, Tallaght, Trinity College Dublin, Ireland  \n5,8 Department of Pharmacology and Therapeutics, Trinity Health Sciences, Trinity College Dublin, Ireland  \n*Corresponding Author: [tomi.wamena@gmail.com](tomi.wamena@gmail.com)  \nABSTRACT  \nBased on WHO and UNAIDS reports in 2021, 38.4 million (33.9-43.8 million) HIV cases in the world, in Indonesia reported by 34 provinces, the number of people living with HIV found in the January-March 2022 period was 10,525 941,973 people have HIV, and 8,784 people are receiving ARV treatment. The aim of this study is to observe the literature on the clinical efficacy, safety, compliance and risk compliance of oral pre-exposure prophylaxis (PrEP) for HIV prevention in all population groups. A literature review was carried out by identifying national and international articles regarding pre-exposure prophylaxis (PrEP) for preventing HIV transmission. The database used was Google Scholar, Pubmed, Science Direct, The Lancet. There were 331 articles searched from the Pubmed online database, 14 articles, Proquest 134, Science Direct 105, The Lancet 2, Google Scholar 105. There were 20 articles that met the inclusion criteria and were processed. In qualitative synthesis. In conclusion, there is very strong evidence that PrEP is safe and effective for HIV prevention in MSM and serodiscordant couples, assuming adequate compliance. The importance of supportive care to ensure that PrEP is effective and the need for frequent HIV testing at warm-up and follow-up to avoid medication antiviral resistance.  \nKeywords: Human Immunodeficiency Virus (HIV), pre-exposure prophylaxis (PrEP), safety  \nReceived September 5, 2023; Revised October 10, 2023; Accepted November 10, 2023  \nSTRADA : Jurnal Ilmiah Kesehatan, its website, and the articles published there in are licensed under a Creative Commons Attribution-NonCommercialShareAlike 4.0 International License.  \nCopyright © 2023 Institut Ilmu Kesehatan STRADA Indonesia  \nBACKGROUND  \nBased on WHO and UNAIDS reports in 2021, there were 38.4 million (33.9-43.8 million) HIV cases in the world, while in Indonesia, as reported by 34 provinces, the number of people living with HIV found in the January-March 2022 period was 10,525 people out of 941,973 people were tested for HIV, and 8,784 people received ARV treatment. HIV or human immunodeficiency virus is the agent that causes HIV infection, AIDS or acquired immunodeficiency virus is the highest stage of HIV infection. Controlling human immunodeficiency virus (HIV) infection is one development goals in Indonesia. According to the National Medium Term Development Plan (RPJMN) 2020-2024, the target for the incidence of new HIV infections in 2024 is 0.18 per 1,000 population, much lower than the 2018 target of 0.24 per 1,000 population. This is in line with the global goal to end the HIV epidemic by 2030, known as Triple Zero, with zero new infections as one of the main pillars. Antiretroviral therapy (ARV) is widely recommended for all people living with HIV, regardless of level of immunosuppression. In addition, WHO also recommends preventive/prophylactic treatment with ARVs, known as pre-exposure prophylaxis (PrEP), as part of and in addition to the comprehensive preventive measures that have been and are being taken. PrEP has been introduced in several countries and has been shown to reduc","cbCaih4mKIJ16E7q","https://ap.wps.com/l/cbCaih4mKIJ16E7q","pdf",193739,"English","# Abstract\n# Background\n# Methods","[{\"question\":\"What is the study’s objective regarding PrEP for HIV prevention?\",\"answer\":\"To examine literature on the clinical efficacy, safety, adherence/compliance, and risk compensation of oral pre-exposure prophylaxis (PrEP) across all population groups.\"},{\"question\":\"Which databases were used for the literature review?\",\"answer\":\"The review used Google Scholar, PubMed, Science Direct, and The Lancet to identify national and international articles about PrEP for preventing HIV transmission.\"},{\"question\":\"What key conclusion does the study reach about PrEP’s effectiveness and safety?\",\"answer\":\"PrEP is concluded to have very strong evidence for being safe and effective for HIV prevention in MSM and serodiscordant couples, assuming adequate compliance, with emphasis on supportive care and frequent HIV testing.\"}]","Oral Pre-Exposure Prophylaxis (PrEP) for HIV Prevention - Clinical Effectiveness, Safety, Adherence, and Risk Compensation | PDF",1790555523,23]